Comparison of The Gastrointestinal Side Effects of Selective COX-2 Inhibitor Celecoxib and Indomethacin in Patients With Osteoarthritis

NSAIDs and Gastric Findings


Abstract views: 50 / PDF downloads: 20

Authors

  • Sibel Ada Istanbul Prof. Dr. Cemil Taşçıoğlu City Hospital, Department of Nephrology, Istanbul, Türkiye https://orcid.org/0000-0001-5692-3531
  • Fatma Laika Karabulut Istanbul Prof. Dr. Cemil Taşçıoğlu City Hospital, Department of Gastroenterology, Istanbul, Türkiye https://orcid.org/0000-0002-1435-3400
  • Melek Özer Istanbul Prof. Dr. Cemil Taşçıoğlu City Hospital, Department of Rheumatology, Istanbul, Türkiye

DOI:

https://doi.org/10.5281/zenodo.11214305

Keywords:

Nonsteroidal anti-inflammatory drugs, gastroduodenal lesions, celecoxib, indomethacin, proton pump inhibitors

Abstract

Background: Nonsteroidal anti-inflammatory drugs are commonly prescribed for osteoarthritis management but are associated with gastrointestinal (GI) adverse events. This study aimed to compare GI findings in patients receiving indomethacin and celecoxib for osteoarthritis.

Methods: A retrospective analysis was conducted on 50 patients (42 females, 8 males) with osteoarthritis, divided into indomethacin (n=25) and celecoxib (n=25) groups. Clinical data, including age, gender, disease duration, and H. pylori status, were collected. Baseline and post-treatment gastroduodenoscopy findings were compared between groups.

Results: No cases of GI bleeding were reported. Indomethacin use was associated with a higher risk of gastroduodenal lesions compared to celecoxib (p<0.05). Celecoxib combined with proton pump inhibitors (PPIs) showed a slight improvement in gastric lesions. H. pylori prevalence was 86% in the study population.

Conclusion: Despite the absence of GI adverse events, indomethacin use posed a higher risk of gastroduodenal lesions compared to celecoxib. The addition of PPIs appeared to mitigate GI adverse events, particularly in the celecoxib group. Individualized treatment approaches balancing therapeutic benefits and potential adverse effects are essential in osteoarthritis management. Further research with larger sample sizes and longer follow-up durations is warranted to validate these findings.

References

Tsang A, Von Korff M, Lee S, et al. Common chronic pain conditions in developed and developing countries: gender and age differences and comorbidity with depression-anxiety disorders [published correction appears in J Pain. 2009 May;10(5):553. Demytteneare, K [added]]. J Pain. 2008;9(10):883-891. doi:10.1016/j.jpain.2008.05.005

Vina ER, Kwoh CK. Epidemiology of osteoarthritis: literature update. Curr Opin Rheumatol. 2018;30(2):160-167. doi:10.1097/BOR.0000000000000479

Johnson VL, Hunter DJ. The epidemiology of osteoarthritis. Best Pract Res Clin Rheumatol. 2014;28(1):5-15. doi:10.1016/j.berh.2014.01.004

Osteoarthritis. https://www.who.int/news-room/fact-sheets/detail/osteoarthritis. Accessed at: 11.04.2024

Sinusas K. Osteoarthritis: diagnosis and treatment [published correction appears in Am Fam Physician. 2012 Nov 15;86(10):893]. Am Fam Physician. 2012;85(1):49-56.

Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee [published correction appears in Arthritis Care Res (Hoboken). 2021 May;73(5):764]. Arthritis Care Res (Hoboken). 2020;72(2):149-162. doi:10.1002/acr.24131

Liu X, Machado GC, Eyles JP, Ravi V, Hunter DJ. Dietary supplements for treating osteoarthritis: a systematic review and meta-analysis. Br J Sports Med. 2018;52(3):167-175. doi:10.1136/bjsports-2016-097333

Coxib and traditional NSAID Trialists' (CNT) Collaboration, Bhala N, Emberson J, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769-779. doi:10.1016/S0140-6736(13)60900-9

Richard MJ, Driban JB, McAlindon TE. Pharmaceutical treatment of osteoarthritis. Osteoarthritis Cartilage. 2023;31(4):458-466. doi:10.1016/j.joca.2022.11.005

Gregori D, Giacovelli G, Minto C, et al. Association of Pharmacological Treatments With Long-term Pain Control in Patients With Knee Osteoarthritis: A Systematic Review and Meta-analysis. JAMA. 2018;320(24):2564-2579. doi:10.1001/jama.2018.19319

Chan FKL, Ching JYL, Tse YK, et al. Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial. Lancet. 2017;389(10087):2375-2382. doi:10.1016/S0140-6736(17)30981-9

García-Rayado G, Navarro M, Lanas A. NSAID induced gastrointestinal damage and designing GI-sparing NSAIDs. Expert Rev Clin Pharmacol. 2018;11(10):1031-1043. doi:10.1080/17512433.2018.1516143

Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019;27(11):1578-1589. doi:10.1016/j.joca.2019.06.011

Bruyère O, Honvo G, Veronese N, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019;49(3):337-350. doi:10.1016/j.semarthrit.2019.04.008

D'Arcy Y, McCarberg B. Managing Patient Pain: A Focus on NSAID OTC Formulations for Relief of Musculoskeletal and Other Common Sources of Pain. J Fam Pract. 2018;67(8 suppl):S67-S72.

Lo V, Meadows SE, Saseen J. When should COX-2 selective NSAIDs be used for osteoarthritis and rheumatoid arthritis?. J Fam Pract. 2006;55(3):260-262.

Bakhriansyah M, Souverein PC, de Boer A, Klungel OH. Gastrointestinal toxicity among patients taking selective COX-2 inhibitors or conventional NSAIDs, alone or combined with proton pump inhibitors: a case-control study. Pharmacoepidemiol Drug Saf. 2017;26(10):1141-1148. doi:10.1002/pds.4183

Stiller CO, Hjemdahl P. Lessons from 20 years with COX-2 inhibitors: Importance of dose-response considerations and fair play in comparative trials. J Intern Med. 2022;292(4):557-574. doi:10.1111/joim.13505

Sostres C, Gargallo CJ, Arroyo MT, Lanas A. Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract Res Clin Gastroenterol. 2010;24(2):121-132. doi:10.1016/j.bpg.2009.11.005

Zamani M, Ebrahimtabar F, Zamani V, et al. Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther. 2018;47(7):868-876. doi:10.1111/apt.14561

Kaplan M, Tanoglu A, Duzenli T, Tozun AN. Helicobacter pylori treatment in Turkey: Current status and rational treatment options. North Clin Istanb. 2019;7(1):87-94. Published 2019 Jul 11. doi:10.14744/nci.2019.62558

Lazzaroni M, Bianchi Porro G. Nonsteroidal anti-inflammatory drug gastropathy and Helicobacter pylori: the search for an improbable consensus. Am J Med. 2001;110(1A):50S-54S. doi:10.1016/s0002-9343(00)00636-7

Demir ME, Horoz M, Ulas T, Eren MA, Ercan Z. Nonsteroidal anti-inflammatory drug-induced severe hyponatremia. Medicina (Kaunas). 2012;48(12):619-621.

Aljadhey H, Tu W, Hansen RA, Blalock S, Brater DC, Murray MD. Risk of hyperkalemia associated with selective COX-2 inhibitors. Pharmacoepidemiol Drug Saf. 2010;19(11):1194-1198. doi:10.1002/pds.2011

Wang Y, Fan M, Wang H, et al. Relative safety and efficacy of topical and oral NSAIDs in the treatment of osteoarthritis: A systematic review and meta-analysis. Medicine (Baltimore). 2022;101(36):e30354. doi:10.1097/MD.0000000000030354

Downloads

Published

2024-05-19

How to Cite

Ada, S., Karabulut, F. L., & Özer, M. (2024). Comparison of The Gastrointestinal Side Effects of Selective COX-2 Inhibitor Celecoxib and Indomethacin in Patients With Osteoarthritis: NSAIDs and Gastric Findings . Journal of European Internal Medicine Professionals, 2(2). https://doi.org/10.5281/zenodo.11214305